Bausch Health Files Patent Infringement Lawsuit In The U.S. District Court For The District Of New Jersey Against Norwich Pharmaceuticals
Portfolio Pulse from Benzinga Newsdesk
Bausch Health has filed a patent infringement lawsuit against Norwich Pharmaceuticals in the U.S. District Court for the District of New Jersey. The lawsuit is in response to Norwich's ANDA submission to the FDA for a generic version of XIFAXAN® (rifaximin) 550 mg tablets, used to treat IBS-D.
June 20, 2024 | 9:31 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Bausch Health has initiated a patent infringement lawsuit against Norwich Pharmaceuticals to protect its XIFAXAN® product. This legal action could delay the entry of a generic version into the market, potentially preserving Bausch Health's market share and revenues from XIFAXAN®.
The lawsuit aims to protect Bausch Health's market share for XIFAXAN® by potentially delaying the approval and market entry of a generic version. This could positively impact Bausch Health's short-term stock price as it preserves revenue from a key product.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100